Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium Jill R. DietzMeena S. MoranKatharine A. Yao Editorial Open access 24 April 2020 Pages: 487 - 497
Healthcare providers’ adherence to breast cancer guidelines in Europe: a systematic literature review Ena Niño de GuzmánYang SongIgnacio Ricci-Cabello Review Open access 06 May 2020 Pages: 499 - 518
HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas Tiansheng ShenHiroaki NittaZaibo Li Preclinical study 25 April 2020 Pages: 519 - 527
MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients Brian G. HuntChristina A. WickerSusan E. Waltz Preclinical study 27 April 2020 Pages: 529 - 540
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer Abrar I. AljohaniChitra JosephEmad A. Rakha Preclinical Study Open access 29 April 2020 Pages: 541 - 551
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies E. S. StovgaardM. BokharaeyE. Balslev Preclinical study 02 May 2020 Pages: 553 - 560
Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study Ruo-Xi WangPeng JiSheng Chen Preclinical study 02 May 2020 Pages: 561 - 570
Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy Sharon A. O’TooleCathy SpillaneJohn J. O’Leary Preclinical study Open access 06 May 2020 Pages: 571 - 580
The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers Inge-Marie ObdeijnRitse M. MannMaartje J. Hooning Clinical trial Open access 24 April 2020 Pages: 581 - 588
Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts Mengmeng JiaXi LinRengaswamy Sankaranarayanan Clinical trial 27 April 2020 Pages: 589 - 597
Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation Ennie BijkerkSander M. J. van KuijkStefania M. H. Tuinder Clinical trial Open access 28 April 2020 Pages: 599 - 610
A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction Utku DolenMelissa ThorntonTerence M. Myckatyn Clinical trial 30 April 2020 Pages: 611 - 621
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015 Peter H. O’DonnellVassily Trubetskoythe Translational Breast Cancer Research Consortium (TBCRC) Clinical trial 06 May 2020 Pages: 623 - 633
Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography Asha Heydon-WhiteHiroo SuamiKaren C. Peebles Clinical trial 06 May 2020 Pages: 635 - 644
Chemotherapy use near the end-of-life in patients with metastatic breast cancer Luisa Edman KesslerJohnny SigfridssonAlexios Matikas Clinical trial Open access 07 May 2020 Pages: 645 - 651
Medical costs associated with metastatic breast cancer in younger, midlife, and older women Justin G. TrogdonChristopher D. BaggettStephanie B. Wheeler Epidemiology 28 April 2020 Pages: 653 - 665
Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study Inés Gómez-AceboTrinidad Dierssen-SotosJavier Llorca Epidemiology Open access 30 April 2020 Pages: 667 - 678
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors Chun WangZhaomei MuHushan Yang Epidemiology 04 May 2020 Pages: 679 - 689
Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment? Kadri Altundag Letter to the Editor 27 April 2020 Pages: 691 - 691
Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life Leonardo Ribeiro SoaresVictor Domingos Lisita RosaRuffo Freitas-Junior Letter to the Editor 29 April 2020 Pages: 693 - 694